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Summary
 
Heat-labile 
 
Escherichia coli
 
 enterotoxin (LT) has the innate property of being a strong mucosal
immunogen and adjuvant. In the attempt to reduce toxicity and maintain the useful immuno-
logical properties, several LT mutants have been produced. Some of these are promising mu-
cosal adjuvants. However, so far, only those that were still toxic maintained full adjuvanticity.
In this paper we describe a novel LT mutant with greatly reduced toxicity that maintains most
of the adjuvanticity. The new mutant (LTR72), that contains a substitution Ala 
 
®
 
 Arg in po-
sition 72 of the A subunit, showed only 0.6% of the LT enzymatic activity, was 100,000-fold
less toxic than wild-type LT in Y1 cells in vitro, and was at least 20 times less effective than
wild-type LT in the rabbit ileal loop assay in vivo. At a dose of 1 
 
m
 
g, LTR72 exhibited a mu-
cosal adjuvanticity, similar to that observed with wild-type LT, better than that induced by the
nontoxic, enzymatically inactive LTK63 mutant, and much greater than that of the recombi-
nant B subunit. This trend was consistent for both the amounts and kinetics of the antibody in-
duced, and priming of antigen-specific T lymphocytes. The data suggest that the innate high
adjuvanticity of LT derives from the independent contribution of the nontoxic AB complex
and the enzymatic activity. LTR72 optimizes the use of both properties: the enzymatic activity
for which traces are enough, and the nontoxic AB complex, the effect of which is dose depen-
dent. In fact, in dose–response experiments in mice, 20 
 
m
 
g of LTR72 were a stronger mucosal
adjuvant than wild-type LT. This suggests that LTR72 may be an excellent candidate to be
tested in clinical trials.
 
H
 
eat-labile enterotoxin (LT)
 
1
 
 produced by enterotoxi-
genic 
 
Escherichia coli
 
 strains (1) and cholera toxin (CT)
produced by 
 
Vibrio cholerae
 
 strains (2) are the causative agents
of traveler’s diarrhea and cholera, respectively. They show
80% homology in the primary structure (3, 4) and a similar
3-D structure (5). Both toxins are composed of two function-
ally distinct domains: the enzymatically active A subunit with
ADP-ribosylating activity (6–8), and the pentameric B subunit
that contains the monosialoganglioside (GM1) receptor–bind-
ing site (9, 10). The A subunit intoxicates eukaryotic cells
by activating the protein Gs, a GTP-binding protein that reg-
ulates the levels of the second messenger cAMP (11, 12). In
vivo, enhancement in cAMP levels alter ion transport, induc-
ing secretion of water and chloride ions in the intestine (13).
Both CT and LT have the unique property of being very
immunogenic by the oral and other mucosal routes, where
most antigens are unable to induce an immune response.
Even more interesting is the fact that they act as potent
mucosal adjuvants and induce an immune response against
coadministered antigens (14, 15). The adjuvanticity and the
immunogenicity of CT and LT have been extensively
studied in animal models with the aim of understanding the
basis for these unique features and in order to develop mu-
cosally delivered vaccines (16–18). However, their toxicity
has precluded their use in humans (19). To overcome the
problem of toxicity and understand the mechanism of ac-
tion, two different approaches have been followed, one
based on the use of the nontoxic B subunit (20, 21), and
the other based on the generation of genetically detoxified
derivatives of LT (22, 23) and CT (24, 25) by site-directed
mutagenesis. These studies have shown that the most im-
 
1
 
Abbreviations used in this paper:
 
 CT, cholera toxin; LT, heat-labile entero-
toxin; rLTB, recombinant B subunit of LT.
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portant factor for immunogenicity is the ability to bind the
receptor on eukaryotic cells. In fact, a nonbinding mutant
of the B subunit of LT, containing the mutation Gly 33 
 
®
 
Asp, was found to be nonimmunogenic (26). On the other
hand, the ADP-ribosylating activity was found unnecessary
for immunogenicity since we and others showed that non-
toxic derivatives of LT obtained by site-directed mutagen-
esis of the A subunit retained the immunological properties
of the wild-type LT (23, 27, 28).
In the case of adjuvanticity, the results are less clear. Ini-
tially, the B subunit of LT (LTB) and that of CT (CTB)
were reported to have an adjuvant effect. However, subse-
quent studies showed that those results had been compro-
mised by the use of preparations contaminated by the ac-
tive toxin (29). The use of recombinant LTB and CTB,
free of contaminating enzymatic activity, confirmed that
the B subunits are very poor mucosal adjuvants (30–32).
This suggested that either the nontoxic A subunit per se or
the enzymatic activity, or both, are necessary for adjuvan-
ticity. The attempt to define the role of ADP-ribosylating
activity in LT adjuvanticity has generated conflicting re-
sults. Lycke et al. (30) described a nontoxic derivative of
LT (LTE112K) that, when coadministered with KLH by
the oral route in mice, lacked the adjuvant properties of the
wild-type LT, thus suggesting that the adjuvant activity of
LT is linked to its ADP-ribosylating activity. We showed
that LT derivatives (e.g., LTK7 and LTK63; references 32–
34) devoid of any enzymatic activity and toxicity were still
able to elicit an antibody response against the coadminis-
tered antigen in intranasally immunized mice. One of the
mutants tested, LTK63, after intranasal immunization with
a synthetic peptide, induced measles virus-specific CTL re-
sponse (35), and strongly enhanced protection against 
 
Heli-
cobacter pylori
 
 after intragastric immunization with 
 
H. pylori
 
antigens (36, 37). However, the antibodies induced by the
nontoxic LT mutants were somehow lower in titer and ap-
peared later than when the wild-type toxin was used (32–34).
To address the above questions, we have produced a
new LT mutant (LTR72) with greatly reduced enzymatic
activity and toxicity, and compared its adjuvanticity and
immunogenicity with those of the toxic wild-type LT, of a
nontoxic AB molecule (LTK63), and of the nontoxic B
subunit. For the first time, the results give a consistent pic-
ture of the relative role of the B subunit, the AB complex,
and the enzymatic activity on the immunological proper-
ties of LT, and they show that a mutant such as LTR72
may be an optimal mucosal adjuvant. In fact, although it
retains the adjuvanticity of wild-type LT, the greatly re-
duced enzymatic activity may allow for safe use in humans.
 
Materials and Methods
 
Computer Modeling and Site-directed Mutagenesis of the LT 
Active Site
 
Mutations in position 72 were designed on the basis of the 3-D
structure of LT (5, 22, 38). Computer analysis was performed on
an INDIGO ELAN workstation (Silicon Graphics, Inc., Moun-
tain View, CA), using the program INSIGHTII (Biosym Technol-
ogies, Inc., San Diego, CA). Energy calculations were performed
using the program DISCOVER (Biosym Technologies, Inc.).
The 2Kb SmaI–HindIII fragment from plasmid pEWD299
containing the LT genes and the LT promoter region (3) was cloned
in Blue-Script KS vector (Stratagene, San Diego, CA) and used as
DNA template for site-directed mutagenesis (39). The mutations in
position 72 were introduced using the following oligonucleotides for
mutagenesis: 5
 
9
 
-GCTCACTTACGTGGACAGTCT-3
 
9
 
 for Ala 
 
®
 
Arg substitution, 5
 
9
 
-GCTCACTTACATGGACAGTCT-3
 
9
 
 for
Ala 
 
®
 
 His, 5
 
9
 
-GCTCACTTAGAGGGACAGTCT-3
 
9
 
 for Ala 
 
®
 
Asp substitution. The mutation in position 63, corresponding to
the Ser 
 
®
 
 Lys substitution, has been previously described (22,
27). DNA manipulations were performed using standard proce-
dures (40).
 
Biochemical Characterization of the LTR72 Mutant
 
Purification.
 
Wild-type LT, LTK63 (Ser 
 
®
 
 Lys), and LTR72
(Ala 
 
®
 
 Arg) mutants, and recombinant B subunit of LT (rLTB)
were purified from the periplasm of the recombinant 
 
E. coli
 
 strain
using three chromatographic steps on CPG 350 (Controlled Pore
Glass; Serva, Heidelberg, Germany), A5m agarose (Bio-Rad Lab-
oratories, Richmond, CA), and Sephacryl S-200 (Pharmacia Bio-
tech AB, Uppsala, Sweden) resins as described (28, 41). The puri-
fied LTR72 protein was stored at 4
 
8
 
C and every 2 mo 100-
 
m
 
l
samples were analyzed by HPLC using a Superdex 200 HR
(Pharmacia Biotech AB) gel filtration column.
 
Trypsin Treatment.
 
LT, LTR72, or LTK63 mutant proteins
(45 
 
m
 
g) were treated with 9 
 
m
 
g of trypsin (Sigma Chemical Co.,
St. Louis, MO) in a final volume of 150 
 
m
 
l of 10 mM Tris, pH
7.5, at 37
 
8
 
C. 30-
 
m
 
l samples were collected after 5 and 30 min of
incubation and the reaction was stopped by the addition of 3.6
 
m
 
g of trypsin inhibitor (Sigma Chemical Co.). 10 
 
m
 
l of 4
 
3
 
 con-
centrated electrophoresis sample buffer was added to each sample
and the mixture was treated for 10 min at 95
 
8
 
C. Proteins were
loaded on 15% SDS minigels and stained with Coomassie brilliant
blue R-250 (Bio-Rad), or transferred onto a nitrocellulose mem-
brane. In this case the membrane was incubated with a rabbit
anti-LT polyclonal sera at a dilution of 1:300.
 
Functional Characterization of the LTR72 Mutant
 
ADP-ribosylation Assay.
 
Different amounts of purified wild-
type LT and LT mutants were analyzed for their ability to ADP-
ribosylate polyarginine as described by Lai et al. (42).
 
In Vitro and In Vivo Toxicity.
 
Toxicity of the mutants was
tested in vitro using Y1 cells (43) and in vivo using the rabbit ileal
loop assay as previously described (44). For the Y1 cells assay, se-
rial twofold dilutions of LT, LTR72, LTK63, or rLTB were
added to 5 
 
3
 
 10
 
4
 
 cells/well on 96-well plates. The cells were
then observed for morphological changes after 48 h. For the
rabbit ileal loop assay, two New Zealand adult rabbits, 
 
z
 
2.5 Kg
each, were used for each assay. 1-ml samples with various amounts
of LT or LT mutants were injected into each loop. After 18-20 h,
the liquid accumulated in each loop was collected and measured
with a syringe. The experiment was performed four to six times
in duplicate and the results are expressed as milliliters per centi-
meter.
 
Immunization of Mice
 
Mucosal immunogenicity and adjuvanticity of wild-type LT,
LTR72 and LTK63 mutants, and rLTB were tested by immuniz-
ing groups of 10 BALB/c mice (4–6-wk-old females; Charles 
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River, Calco, Italy) intranasally with 1 
 
m
 
g of toxin and 10 
 
m
 
g of
antigen, or with antigen alone. In the dose–response experiment,
five mice were immunized with a constant amount of OVA (10
 
m
 
g) and varying doses of wild-type LT, LTR72 (2.5 ng, 50 ng, 1 
 
m
 
g,
and 20 
 
m
 
g), or LTK63 (50 ng, 1 
 
m
 
g, and 20 
 
m
 
g).
The animals were lightly anesthetized and immunized on days
0, 21, and 35 with a 15-
 
m
 
l volume per nostril. Immune responses
were followed in the serum samples taken on days 0, 20, 34, and
52. The animals were killed and nasal lavages were performed by
repeated flushing and aspiration of 1 ml of PBS containing 0.1%
BSA (Sigma Chemical Co.).
 
Quantitation of Anti-OVA and Anti-LT Antibodies
by ELISA
 
LT-specific antibodies were measured using a GM1 capture
ELISA. Each well on 96-well plates (Greiner GmbH, Kremsmun-
ster, Austria) was first coated with 150 ng of GM1 ganglioside
(Sigma Chemical Co.) by overnight incubation at 4
 
8
 
C. Wells
were then washed three times with PBS containing 0.05% Tween
20, and 50 ng of toxin were added to each well. Plates were then
incubated for 2 h at 37
 
8
 
C. OVA-specific antibodies were assessed
by coating each well with 60 
 
m
 
g/ml of OVA and incubated over-
night at 4
 
8
 
C. The plates were washed and the wells were satu-
rated with 1% BSA in PBS for 1 h at 37
 
8
 
C. Sera from individual
mice were tested starting from a dilution of 1:50 in PBS and nasal
lavages were tested starting from undiluted solution. Plates were
incubated for 2 h at 37
 
8
 
C. Specific Ig were measured using a
horseradish peroxidase–conjugated rabbit anti–mouse Ig (Dako,
Glostrup, Denmark) (2 h at 37
 
8
 
C). Antibodies were then revealed
by adding 
 
o
 
-phenylenediamine (OPD) as substrate (Sigma Chem-
ical Co.). After 10 min the reaction was blocked by the addition
of 12.5% H
 
2
 
SO
 
4
 
 and the absorbance was read at 490 nm. ELISA
titers were expressed as the reciprocal of the last dilution which
gave on OD
 
490
 
 
 
>
 
0.3 above the preimmune sera. Titers of specific
IgA in the sera and in the mucosal lavages were measured using
the biotin-conjugated goat anti–mouse IgA (
 
a
 
 chain–specific;
Sigma Chemical Co.) followed by horseradish peroxidase–conju-
gated streptavidin. Bound antibodies were revealed using OPD as
substrate. ELISA titers were expressed as the reciprocal of the last
dilution which gave on OD
 
490
 
 
 
>
 
0.2 above the preimmune sera.
The values were normalized using positive control sera in each
plate.
 
OVA-driven Proliferative Response
 
14–20 d after two intranasal immunizations with LT or LT
mutants in combination with OVA, two or three mice per group
were killed and spleens were removed. Spleen cell suspensions
were obtained and resuspended in complete DMEM containing
10% FCS, 2 mM 
 
L
 
-glutamine, 15 mM Hepes, 100 U of penicil-
lin/streptomycin, and 50 mM 2-ME. 2 
 
3
 
 10
 
5
 
 spleen cells were
seeded per well in U-bottomed 96-well plates and cultured in the
presence of different concentration of OVA for 5 d. [
 
3
 
H]thimi-
dine was added (1 
 
m
 
Ci/well) 16 h before the end of culture. Cells
were then harvested with a cell harvester, and [
 
3
 
H]thimidine in-
corporation was evaluated by liquid scintillation counting.
 
In Vivo Challenge with Wild-type LT
 
To determine the LD
 
50
 
 for wild-type LT by intraperitoneal
route, groups of 10 BALB/c mice (9-wk-old females) were inoc-
ulated intraperitoneally with 12.5, 25, 50, and 100 
 
m
 
g of LT. The
control group was inoculated with PBS. The mice were observed
for death for 7 d. LD
 
50
 
 was determined as 20.4 
 
m
 
g. Then, 4-wk-
old BALB/c mice were immunized intranasally with 1 
 
m
 
g each of
LT, LTR72, LTK63, and LTB at days 0 and 21, and challenged
with 2 
 
3
 
 LD
 
50
 
 of wild-type LT at day 35. The mice were ob-
served for deaths for 7 d. Sera were collected at day 35 and anti-
LT titers were analyzed by ELISA as described above.
 
Results
 
Biochemical and Biological Characterization of the LTR72
Mutant.
 
After site directed mutagenesis of the A subunit
of LT, we described, among other mutants, three mutants
of the Alanine in position 72, an amino acid located in the
internal face of the 
 
a
 
 helix that forms the cavity containing
the nicotinamide adenine dinucleotide (NAD) binding site
(22, 45). When tested in crude periplasmic extracts, two of the
mutants showed some reduced toxicity in Y1 cells, suggest-
ing that they could be potentially useful when LT mutants
with some residual toxicity were needed (22). Subsequent
analysis of purified preparations of the three mutants showed
that although LTH72 (Ala 
 
®
 
 His) and LTE72 (Ala 
 
®
 
 Glu)
had a toxicity indistinguishable from that of wild-type
toxin (data not shown), the mutant LTR72 (Ala 
 
®
 
 Arg)
showed greatly reduced toxicity. We therefore decided to
further study this mutant and compare it to wild-type LT
and to other nontoxic mutants previously obtained and
characterized. Fig. 1 
 
A
 
 shows the elution profile on Super-
dex 200 HR column of LTR72, LTK63, and wild-type LT.
The three molecules had an identical elution profile, sug-
gesting that the mutation Ala72 
 
®
 
 Arg does not alter the
structure of the A subunit, and that this is correctly assem-
bled into the AB
 
5
 
 structure. This elution profile remained
unchanged up to 1 yr after storage of the LTR72 mutant at
4
 
8
 
C, suggesting that the molecule is also very stable (data
not shown). To check whether minor conformational changes
were present, we tested the sensitivity to proteases. Purified
wild-type LT, LTK63, and LTR72 mutants were treated
with trypsin at 37
 
8
 
C, and samples were collected at differ-
ent times and analyzed by Western blot. The results (Fig. 1
 
B
 
), showed that after 5 min of incubation, in all three mol-
ecules the trypsin caused an almost immediate nicking of
the A subunit into the A1 and A2 domains, and that the nick-
ing was complete after 30 min of incubation. No differ-
ences were detected in the sensitivity to proteases between
LTR72, wild-type LT, or LTK63. Then we tested various
functional activities. In vitro, the LTR72 mutant exhibited,
as compared to wild-type LT, an ADP-ribosylation activity
that was reduced by at least two orders of magnitude: the
minimal amount to obtain a detectable activity was 0.5 
 
m
 
g
for LT and 85 mg for LTR72. As expected, the LTK63
mutant was totally devoid of enzymatic activity (Fig. 1 C).
In agreement with the reduced catalytic activity, the
LTR72 was 100,000-fold less toxic than wild-type LT on
Y1 cells (Fig. 1 D). In the rabbit ileal loop assay, at least a
20-fold higher amount of LTR72 was needed to start to
induce a fluid accumulation. However, this mutant was
never able to induce more than 1.5 ml/cm of fluid at any
of the amounts tested (up to 200 mg), whereas LT induced
.3.0 ml/cm already at very low amounts (50 ng; Fig. 1 E).1126 Mucosal Adjuvants and Immunogens
As previously reported, LTK63 was completely nontoxic
both in Y1 cells and in the rabbit ileal loop assay (46).
Mucosal Adjuvanticity of LTR72. Groups of mice were
immunized intranasally three times with 10 mg of OVA
alone or with 10 mg of OVA and 1 mg of wild-type LT,
LTR72, LTK63, or rLTB. Serum anti-OVA specific anti-
body titers were determined after each immunization. As
shown in Fig. 2, wild-type LT and the mutant LTR72 in-
duced the highest anti-OVA antibody response. LTK63 in-
duced an intermediate level; the B subunit gave quite a low
response. The antigen-specific antibody response was de-
tectable already after a single immunization with LT and
LTR72, whereas, as previously described (33, 34), the non-
toxic LTK63 mutant required at least two immunizations
to induce anti-OVA antibodies in serum.
OVA-specific IgG isotypes were measured in pools of
sera of the last bleeding (Fig. 3). High titers of anti-OVA
IgG1, IgG2a, and IgG2b antibodies were induced in the
groups of mice receiving the wild-type LT or the LTR72
mutant as an adjuvant. IgG2b antibodies were almost unde-
tectable in the mice receiving the nontoxic LTK63 mutant.
OVA-specific IgG3 antibodies were never detectable. It is
interesting to note that, in the presence of wild-type LT,
the predominant antigen-specific IgG subclass was the
IgG2a, whereas in the presence of the mutant LTR72 and
LTK63, higher titers of serum anti-OVA IgG1 were de-
tected. Finally, in the group of mice receiving OVA in the
presence of LTB, only very low titers of anti-OVA IgG1
antibodies were found.
In all experiments, OVA-specific IgA antibodies were
never detectable in sera of mice after one or two intranasal
immunizations (data not shown). After a third immuniza-
tion, a serum IgA response was detected when wild-type
LT or the mutants LTR72 and LTK63 were used as adju-
vants (Fig. 4 A). Mice immunized with the rLTB plus
OVA did not show any detectable IgA response, whereas
only one mouse of the control group (i.e., those receiving
OVA without any adjuvant) showed detectable titers of
anti-OVA IgA. A similar pattern of IgA response was ob-
served at the mucosal level. After three immunizations,
Figure 1. Comparison of biochemical and biological properties of LTR72, LTK63, and wild-type LT. (A) Chromatographic profiles of LTR72,
LTK63 and wild-type LT on Superdex column (peak I corresponds to the holotoxin, peak II to the EDTA contained in the buffer). (B) Western blot of
the untreated wild-type LT and of the wild-type LT, LTR72, and LTK63 after 5 and 30 min of incubation with trypsin. (C) In vitro ADP-ribosylation
using polyarginine as substrate. (D) In vitro toxicity on Y1 cells at 48 h. (E) In vivo toxicity in the rabbit ileal loop assay.1127 Giuliani et al.
OVA-specific IgA antibodies were found in nasal washes of
mice receiving the antigen along with wild-type LT,
LTR72, or LTK63, but not in the absence of adjuvants or
in the presence of rLTB (Fig. 4 B).
OVA-specific T Cell Priming. Spleen cells from mice im-
munized intranasally twice with OVA alone or combined
with a mucosal adjuvant were restimulated in vitro in the
presence of different concentrations of OVA. Fig. 5 shows
the results of a representative experiment. It is clear that in-
tranasal coadministration of the antigen with wild-type LT
or with the LTR72 and LTK63 mutants induced a priming
of OVA-specific T cells in vivo, which was much stronger
than that detectable after immunization with OVA alone or
with OVA given in the presence of rLTB. Interestingly,
the OVA proliferative response induced by LTR72 was
lower than that observed with cells from mice immunized
with OVA plus wild-type LT, but higher than that ob-
served with cells from mice immunized with OVA plus
LTK63.
Comparative Adjuvanticity of LT, LTR72, and LTK63.
The comparative adjuvanticity of LT, LTR72, and LTK63
versus OVA was tested in a dose–response experiment.
Mice were immunized using a constant dose of OVA (10
mg) and doses of mucosal adjuvant ranging from 2.5 ng to
20 mg. As shown in Fig. 6 A, wild-type LT induced high
titers of anti-OVA antibodies already at 2.5 ng, which in-
creased at 50 ng and reached a plateau at 1 mg. No further
increase was observed raising the amount of wild-type LT
to 20 mg. On the contrary, LTR72 and LTK63 showed a
dose response at all amounts tested. The adjuvanticity of
Figure 2. Anti-OVA serum Ig antibody response. Immune responses
to OVA in sera of mice immunized intranasally with OVA alone, or
OVA in combination with wild-type LT, LTR72, LTK63, and LTB, at
time 0 after one, two and three immunizations. Results are expressed as
mean titers of OVA-specific antibodies in the sera of mice on days 0, 20,
34, and 52.
Figure 3. Serum anti-OVA IgG subclasses response. IgG suclasses re-
sponse in sera of mice immunized intranasally with OVA alone, or OVA
in combination with wild-type LT, LTR72, LTK63, and rLTB after three
immunizations. Titers were calculated by using dilutions of pooled sera.
Figure 4. Anti-OVA serum and mucosal IgA antibody responses. IgA
immune responses to OVA in sera (A) and in nasal washes (B) of mice
immunized intranasally three times with OVA alone or OVA in combi-
nation with wild-type LT, LTR72, LTK63, and rLTB. Results are shown
as mean titers and error bars indicate the standard deviation from the
mean titer.
Figure 5. T cell proliferative response to OVA. T cell proliferative re-
sponse to OVA in spleen cells from mice immunized intranasally for two
times with OVA alone or OVA in combination with wild-type LT,
LTR72, LTK63, and rLTB.1128 Mucosal Adjuvants and Immunogens
LTR72 was lower than that of wild-type LT at 2.5 and 50
ng, but at 1 mg it was comparable to that induced at plateau
value by wild-type LT and, remarkably, at 20 mg it was
even higher. The adjuvanticity of LTK63 was similar to
that of LTR72 at 50 ng and increased at 1 mg and 20 mg.
However, the dose–response curve of LTK63 was such
that at 1 mg it reached a value lower than that of wild-type
LT and LTR72, whereas at 20 mg it was similar to that of
wild-type LT and lower than that of LTR72. These data
show that although the adjuvanticity of wild-type LT is sat-
urated after a given dose, possibly because of the detrimen-
tal effects deriving from its toxic properties, the adjuvant
effect of LTR72 and LTK63 increases at higher doses. Fur-
thermore, at high doses LTR72 can be a stronger mucosal
adjuvant than wild-type LT.
Immunogenicity after Mucosal Delivery and Protection against
a Challenge With Wild-type LT. We next addressed the
mucosal immunogenicity and whether the observed im-
mune response protected mice against an intraperitoneal
challenge with the toxic wild-type LT. First, we deter-
mined the LD50 of LT by intraperitoneally inoculating groups
of mice with increasing doses of LT and recording the
mortality rate after 7 d. The determined LD50 was 20.4 mg
(data not shown). Then, groups of mice were immunized
intranasally at days 0 and 21 with 1 mg of LT, LTK63,
LTR72, or rLTB. The control group received diluent only
(PBS). On day 34 mice were challenged intraperitoneally
with 2 3 LD50 of wild-type LT and observed for mortality
for the following 7 d. The results showed that all mice im-
munized with wild-type LT, LTR72, and LTK63 survived
to the challenge, whereas only 30% of mice immunized
with the rLTB survived. As expected, all mice in the con-
trol group died (Fig. 7 A). The serum anti-LT antibody ti-
ters in mice were determined after two imunizations and
just before the challenge; the results are shown in Fig. 7 B.
Sera of mice immunized with LT, LTK63, and LTR72
contained very high and comparable levels of anti-LT anti-
bodies. In mice intranasally immunized with rLTB, anti-
LT antibody titers were 10–20 times lower than those
found in mice immunized with the wild-type LT, or with
the LTR72 or LTK63 mutants. Interestingly, Fig. 7 B also
shows that the three mice immunized with the rLTB that
survived to the intraperitoneal challenge with wild-type LT
had serum anti-LT antibody titers significantly higher than
those found in the sera of immunized mice that did not
survive. These data suggest that serum anti-LT antibody re-
sponse participates in the effector mechanisms mediating
protection against lethal challenge with toxic LT.
Discussion
Safety Profile of LTR72. The unique property of LT to
act as a potent mucosal adjuvant and immunogen has stim-
ulated many studies aimed at understanding the mechanism
of action and generating nontoxic derivatives suitable for
use in human vaccines. Thus far, the best reagents and can-
didate adjuvants for vaccines have been the nontoxic, re-
combinant LTB subunit (47), the nontoxic, enzymatically
inactive LTK63 mutant (33–37), and LTG192, a mutant
containing the Arg ® Gly substitution in position 192, in
the trypsin-sensitive loop of the A subunit. This mutant has
an intact catalytic site but cannot be activated in vitro be-
cause of the resistance of the loop to trypsin digestion. In
vivo, proteases other than trypsin are likely to activate in
part the LTG192. This is because LTG192 on Y1 cells
showed a toxicity 1,000-fold lower than wild-type after an
8-h incubation, whereas it was only 5-fold lower after 24 h
of incubation (46). In the ileal loop, the toxicity of LTG192
was barely distinguishable from that of wild-type LT (46,
48, 49). Here we have described a new mutant in the cata-
lytic site (LTR72) having z100-fold reduced enzymatic
activity, 100,000-fold reduced toxicity in the Y1 cells, and
at least 20-fold reduced toxicity in the rabbit ileal loop assay.
The question is whether LTR72 mutant can be safely
Figure 6. Serum Ig anti-OVA responses in a dose–response experiment. (a) Ig immune response in sera of five mice after three intranasal immuniza-
tions with 10 mg of Ova and 2.5 ng, 50 ng, 1 mg, and 20 mg of wild-type LT or LTR72 and 50 ng, 1 mg, and 20 mg of LTK63. Results are shown as
mean titers and error bars indicate the standard deviation from the mean titer. (b) Schematic representation showing the dose-dependent adjuvanticity of
LTK63, LTR72, and wild-type LT derived from a. The figure shows that the adjuvanticity of the nontoxic AB complex (darker area) is dose dependent,
while the adjuvanticity of the enzymatic activity (lighter area) is dose independent.1129 Giuliani et al.
used in humans. So far the experience in humans is limited:
CTB has been safely used at a 1-mg oral dose (20) and up
to a 100-mg intranasal dose (50). In the case of LT, the only
published information refers to the use of LTG192 (51).
This was safe orally at 5-, 25-, and 50-mg doses, whereas at
a 100-mg dose it induced mild diarrhea in some of the vol-
unteers. Based on the above data, it is likely that LTR72,
which in the rabbit ileal loop is at least 20-fold less toxic
than LTG192, can be used safely in humans at high doses.
Since the immunogenic and adjuvant dose is predicted to
be in the range of 25–200 mg, it is likely that LTR72 has
the appropriate safety window to be safely used in the open
population, including adults and children.
Adjuvanticity Derives from both the Nontoxic AB Complex
and the Enzymatic Activity. rLTB, LTK63, LTR72, and
wild-type LT have been compared in this study to deter-
mine which is the optimal mucosal adjuvant and to under-
stand the role played in adjuvanticity of the following fac-
tors: the B subunit, the nontoxic AB complex, and the
enzymatic activity.
Adjuvanticity is a complex feature because two proper-
ties of LT (the nontoxic AB complex and the enzymatic
activity) seem to contribute independently to the adjuvant
effect. Therefore, the final adjuvanticity of LT results from
both properties. Here we have confirmed that the B sub-
unit is a very poor mucosal adjuvant, whereas LTK63 acts
as a good mucosal adjuvant, showing that the nontoxic AB
complex has an adjuvant effect despite the absence of any
ADP-ribosylating activity. However, the antibody titers to
the coadministered antigens induced by LTK63 were lower
than those obtained using the wild-type toxin and were de-
tected only after two immunizations. In marked contrast,
the mutant LTR72 generated anti-OVA responses after
one intranasal immunization, in a manner equivalent to
that induced by wild-type LT. These data show that the
presence of enzymatic activity enhances the adjuvanticity
of LT mutants. However, the full enzymatic activity of
wild-type LT is not necessary and mutants with only 0.6%
enzymatic activity, such as LTR72, retain most of the adju-
vant properties of wild-type LT. The above conclusions
based on antibody levels were fully confirmed by the ability
of the mutants tested of inducing antigen-specific T cell
proliferative responses: LT and LT mutants, but not rLTB,
were able to enhance priming of OVA-specific CD41 T
lymphocytes. It is reasonable to speculate that this en-
hanced antigen-specific T cell priming was responsible for
an enhanced antigen-specific B cell help, which was at the
basis of the higher and faster OVA-specific IgG and IgA
antibody response in mice receiving LT or LT mutants as
mucosal adjuvants.
A dose–response curve (Fig. 6 A) provided the rationale
for the relative contribution to adjuvanticity of the non-
toxic AB complex and of the enzymatic activity. The ratio-
nale is schematically represented in Fig. 6 B. At a low dose
(2.5 ng), only wild-type LT showed an adjuvant effect,
suggesting that this is entirely due to the enzymatic activity
present in wild-type LT. At higher doses (between 50 ng
and 1 mg), the adjuvant effect of LT and LTK63 showed a
parallel growth, suggesting that the increase observed in
this part of the curve is only due to the enzymatically inac-
tive AB complex present both in LTK63 and LT, and that
the difference is due to the adjuvant effect of the enzymatic
activity present in LT only. At doses higher than 1 mg, the
LT curve reaches a plateau possibly because of toxicity.
The adjuvanticity of LTR72 follows the curve of LTK63 at
very low doses (up to 50 ng), but joins the curve of LT at 1 mg
likely because at this dose the enzymatic activity reaches
the threshold level. Then the adjuvant effect of LTR72
continues to increase along the theoretical curve of wild-
type LT beyond the LT because it is not affected by the
toxicity induced by high doses of LT. In conclusion, the
data confirm that the adjuvant effect derives from the inde-
Figure 7. Protection of intra-
nasal immunization with wild-
type LT, LTR72, and LTK63
against systemic challenge with
wild-type LT. (A) Mice survival
to the challenge with 2 3 LD50
of wild-type LT after two intra-
nasal immunizations with 1 mg of
wild-type LT, LTR72, LTK63,
and LTB. Mice were observed
for 7 d after challenge. (B) Ig
anti-LT immune response in sera
of mice before challenge. Anti-
body titers of individual mice
survived to the challenge are re-
ported as white dots; antibody
titers of mice which did not sur-
vive to the challenge are reported
as black dots.1130 Mucosal Adjuvants and Immunogens
pendent contribution of the enzymatic activity and the
nontoxic AB complex. For the enzymatic activity in our
experiments, 2.5 ng are enough and the increase above this
level does not significantly enhance adjuvanticity. Con-
versely, the adjuvant effect of the nontoxic AB complex is
dose dependent, so that the higher adjuvanticity corre-
sponds to the higher dose. This makes LTR72 an ideal ad-
juvant since, without incurring in problems of toxicity, it
can take advantage of the adjuvant effect induced by the
combination of low levels of enzymatic activity and high
doses of the nontoxic AB complex.
Mechanisms of Adjuvanticity. It is not clear yet through
which mechanism(s) LT and LT molecules exert their
mucosal adjuvanticity. It has been postulated that these mole-
cules may activate macrophages (or possibly other antigen-
presenting cells) by increasing the expression of costimula-
tory molecules such as B7-1 and/or B7-2 (52). However, it
is not possible to rule out that LT may potentiate some in-
tracellular events involved in uptake, processing, and pre-
sentation of antigen by antigen-presenting cells. In the case
of CT, it has been reported that the adjuvant activity of CT
could be mediated by its ability to enhance antigen presen-
tation by macrophages, and this effect has been associated
with increased production of IL-1 (53). Several studies
have shown that CT could enhance production of IL-1 and
IL-6 by macrophages or epithelial cells, and that the ADP-
ribosylation activity of CT could contribute to these effects
(54). In the case of LT, it has been reported that oral im-
munization with wild-type LT promotes B cell isotype
switching and subclass responses to IgG1, IgG2a, IgG2b,
and IgA; it induces a mixed CD41 Th1-Th2–type re-
sponse, and in vitro stimulation of CD41 T cells resulted in
synthesis of IFN-g and IL-5, and low levels of IL-4 (55).
After the results reported in this work, it would be interest-
ing to use the reagents described here to define which of
the above mechanisms is triggered by the enzymatic activ-
ity and which by the nontoxic AB complex.
It is possible that during internalization and retrograde
transport through the Golgi, the A subunit could reach and
interact with some unidentified proteins within the target
cells, altering some signal transduction pathways.
Immunogenicity and In Vivo Protective Efficacy of LT Mu-
tants. Here we have shown that both LTK63 and LTR72
are as immunogenic as wild-type LT and more immuno-
genic than rLTB. This indicates that the enzymatic activity
is not needed and that the receptor binding is not enough
for optimal immunogenicity. We have previously demon-
strated that the nontoxic mutants of LT are able to induce
in vitro neutralizing antibodies against the A subunit when
used to immunize mice and rabbits by systemic route (27,
28), and that mucosal immunization with wild-type LT
and LTK63 induces significant levels of anti-A antibodies
(56). In the present study we have also shown that the lev-
els of anti-LT antibodies induced in mice immunized intra-
nasally with the holotoxin were higher than those induced
in mice immunized with the rLTB. However, so far we
have not addressed the question of whether the anti-A an-
tibodies induced were able to neutralize the toxin in vivo.
Here we have shown that the antibodies induced by intra-
nasal immunization with the mutant holotoxins are more
efficient in the neutralization of the toxic activity of LT in
vivo compared to those induced by the rLTB. The in vivo
mouse model used has been previously proposed for evalu-
ation of antitoxic protective effect of cholera vaccines (57)
and is based on the pathophysiologic effects induced by the
systemic challenge of CT such as weight loss, atrophy of
the spleen and thymus, and, when the dose is high enough,
death (58). We have adopted the same model to LT, and
have shown that all mice immunized intranasally with the
mutant holotoxins were protected from the lethal challenge
with wild-type LT, whereas, of those immunized with
rLTB, only mice with highest antibody titers survived. A
possible explanation is that the presence of an A subunit,
even inactive, could increase the immunogenicity of the
entire molecule, by providing a larger number of T and B
cell epitopes, which may turn out to be those relevant for
the induction of protective immune response. It has been
shown that binding to target cells is required for immuno-
genicity (26) and therefore all the events associated to the
induction of an immune response initiate after the binding
of the toxin to its own receptor. It could be possible that,
after binding and internalization in the antigen-presenting
cells, the A subunit could influence events such as antigen
processing and presentation.
Conclusions. We have shown that although ADP-ribo-
sylation activity is not necessary for the adjuvanticity of LT,
the presence of low levels of enzymatic activity may be
useful to induce a faster and higher immune response to
coadministered antigens. This makes LTR72 an ideal adju-
vant since without incurring problems of toxicity, it can
take advantage of the adjuvant effect of low levels of enzy-
matic activity and of high doses of nontoxic AB complex.
Both LTK63 and LTR72 are excellent mucosal adjuvants
and studies in humans are required to establish which is the
best candidate. Perhaps the slightly different properties of
the two molecules may be exploited for different applica-
tions in different vaccines. The mutants are also very good
immunogens able to induce a protective immunity against
LT and may therefore be useful as components of antidiar-
rheal vaccines.
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